Polyarteritis nodosa

Curr Opin Pediatr. 2022 Apr 1;34(2):229-233. doi: 10.1097/MOP.0000000000001106.


Purpose of review: The aim is to review recent reports on childhood polyarteritis nodosa, including recent reports on treatment and outcome. Recently deficiency of adenosine deaminase-2 (ADA2), which may present as a polyarteritis nodosa-mimic, is becoming an important part of our practice. We also aim to highlight differences of childhood polyarteritis nodosa with deficiency of ADA2 as well as adult-onset disease.

Recent findings: The few recent childhood series confirm the systemic nature of this vasculitis with predominantly medium-vessel involvement. American College of Rheumatology Vasculitis foundation has suggested recommendations for the management of this vasculitis. Unfortunately, we lack large patient numbers to provide us high evidence for the treatment of these patients. However, for induction mycophenolate mofetil or shorter courses of cyclophosphamide can be considered.Deficiency of ADA2 is now in the differential diagnosis of polyarteritis nodosa patients presenting with a family history and/or stroke with hematological and/or immunological abnormalities.

Summary: We need collaborative work to define management and treatment strategies for childhood polyarteritis nodosa. Distinguishing deficiency of ADA2 is important because the treatment is different.

Publication types

  • Review

MeSH terms

  • Adult
  • Agammaglobulinemia
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • Polyarteritis Nodosa* / diagnosis
  • Polyarteritis Nodosa* / therapy
  • Severe Combined Immunodeficiency
  • Vasculitis*


  • Intercellular Signaling Peptides and Proteins

Supplementary concepts

  • Severe combined immunodeficiency due to adenosine deaminase deficiency